Effects of Tegafur, Gimeracil and Oteracil Potassium Capsules combined with Calf Spleen Extractive Injection on serum VEGF and MMP-9 in patients with advanced gastric cancer

Yan Zhang; Qiang Zhong; Xiaochun Luo; Wei Zhang

Effects of Tegafur, Gimeracil and Oteracil Potassium Capsules combined with Calf Spleen Extractive Injection on serum VEGF and MMP-9 in patients with advanced gastric cancer

Am J Transl Res. 2022 Nov 15;14(11):7969-7976. eCollection 2022.

Authors

Yan Zhang^{1

2}, Qiang Zhong³, Xiaochun Luo⁴, Wei Zhang⁵

Affiliations

¹ Department of Gastroenterology, Xiamen Humanity Hospital, Fujian Medical University Xiamen, Fujian, China.
² Department of Gastroenterology, Beijing Pinggu Hospital Beijing, China.
³ Department of Anesthesiology, Xiang'an Hospital of Xiamen University Xiamen, Fujian, China.
⁴ Center for Digestive Endoscopy, Xiang'an Hospital of Xiamen University Xiamen, Fujian, China.
⁵ The First Department of Surgery, Anyang Tumor Hospital Anyang, Henan, China.

PMID: 36505301
PMCID: PMC9730097

Abstract

Objective: To explore the effects of Tegafur, Gimeracil and Oteracil Potassium Capsules (TGOPC) combined with Calf Spleen Extractive Injection (CSEI) on vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) in patients with advanced gastric cancer.

Methods: A retrospective analysis was conducted on data of 118 patients with advanced gastric cancer treated in Anyang Tumor Hospital from January 2016 to September 2018. The patients were divided into two groups according to treatment modalities, with control group receiving Oxaliplatin and TGOPC and observation group receiving Oxaliplatin, TGOPC and CSEI. Clinical efficacy, changes of serum VEGF and MMP-9 before and after chemotherapy, survival rate and incidence of adverse reactions were compared between the two groups.

Results: The number of responded patients was 36 (61.02%) in the observation group and was 18 (30.51%) in the control group (P<0.05). The levels of serum VEGF and MMP-9, and incidence of nausea and vomiting in the observation group were lower than those in the control group (P<0.05). The 1-year and 2-year survival rates in the observation group were higher than those in the control group (P<0.05).

Conclusion: The use of CSEI on the basis of Oxaliplatin combined with TGOPC chemotherapy for the treatment of advanced gastric cancer could further improve the clinical efficacy and survival rate, and reduce the incidence of adverse reactions.

Keywords: Advanced gastric cancer; Calf Spleen Extractive Injection; Gimeracil and Oteracil Potassium Capsules; Oxaliplatin; Tegafur; matrix metalloproteinase-9; vascular endothelial growth factor.